INTRODUCTION
Since its advent in the 1980s, the endoscopic ultrasound (EUS) technology has evolved dramatically, starting first as a supplementary diagnostic modality available only in large medical centers, and now representing a core diagnostic and therapeutic tool that is much more widely available. [1] [2] [3] While the initial focus in the use of EUS had been for diagnosis and management of various gastrointestinal (GI) conditions, ranging from tumor staging and biopsy to evaluation of submucosal lesions, it has also become clear that EUS can provide important clinical and anatomic information with regard to the appearance, size and location of vascular structure. EUS can also allow precise interventions to target certain vascular sites that are inaccessible, or less accessible, using conventional access techniques. By implementing techniques and tools acquired from interventional radiology (IR) and minimally invasive surgery, EUS combines real-time imaging with the possibility of anatomically specific guided vascular treatment. [4] When considering potential opportunities for the development of new EUS-guided vascular approaches, it is important to first take stock of some of the core IR techniques that have been in use for many decades, including selective angiographic embolization for refractory GI bleeding and transjugular intrahepatic portosystemic shunt (TIPS) for refractory gastroesophageal variceal bleeding. [5] The development of EUS-guided vascular access to manage these conditions is feasible owing to the proximity of the GI tract to vascular structures in the mediastinum and the abdomen. Large vessels such as the aorta, celiac axis, portal vein (PV), hepatic vein (HV), mesenteric vessels and aberrant vascular shunts as well as smaller vessels such as the gastroduodenal artery and splenic vessels can be accessed and visualized by EUS. EUS-guided therapies provide a promising, minimally invasive route for accessing vascular structures. Therapeutic agents and devices such as sclerosants, cyanoacrylate (CYA), thrombin and coils can all be delivered using a standard EUS fineneedle aspiration (FNA) into the targeted vessel.
VARICEAL BLEEDING
Endoscopic sclerotherapy and endoscopic band ligation are considered the standard of care for the treatment of esophageal varices. [6, 7] Endoscopic band ligation is the preferred method for primary and secondary treatment of esophageal varices. [8] The reported recurrence rates of 15%-65% are attributed to failure to treat the perforating veins and collateral vessels feeding the esophageal varices. [7] [8] [9] [10] [11] [12] Therefore, alternative, more effective approaches must be considered and evaluated for variceal bleeding.
EUS-guided sclerotherapy has been proven to be effective in a small pilot study by Lahoti et al. [13] The perforating vessels were targeted by EUS-guided needle puncture and injected with sodium morrhuate. The eradication of varices was achieved after a mean of 2.2 sessions. A 15-month follow-up showed no rebleeding or adverse events. EUS-guided sclerotherapy was compared with endoscopic sclerotherapy and no difference was noted in the mean number of sessions needed for eradication and the recurrence rates were not significantly different. However, recurrence was correlated with the identification of collateral vessels (P = 0.003), which was higher in the endoscopic group. [13] EUS-guided therapy of esophageal varices, as promising as it may appear, needs further evaluation by larger, randomized controlled trials to prove its efficacy and cost-effectiveness compared with band ligation and other standard techniques and to identify whether it can best serve as a first-or second-line therapy. The use of CYA glue injection, in place of sclerosant, may also be an alternative approach to consider for EUS-guided treatment. [14] GASTRIC VARICES Gastric varices may be present in up to 20% of patients with portal hypertension. Bleeding from gastric varices can be severe and 35%-90% of the patients rebleed after the initial spontaneous hemostasis. [15] CYA glue injection has become the standard treatment for both acute bleeding and secondary prophylaxis. Hemostasis is achieved in 80%-90% of cases, although rebleeding is a risk. [16] The primary role for EUS in this condition is diagnostic. Gastric varices are located in the deep submucosal layer and may appear similar to the prominent mucosal gastric folds. Boustiere et al. [17] demonstrated that EUS increased the detection of fundal varices sixfold, and thus EUS is a useful tool if gastric varices are suspected, but cannot be confirmed (or targeted) endoscopically.
Endoscopic ultrasound-guided glue injection
EUS-guided glue treatment for gastric varices has an array of potential advantages compared with standard endoscopic glue injection. EUS not only permits accurate delivery of glue into the target varix but also enables the confirmation of complete flow obliteration of the varix using color Doppler. EUS also allows for identification and glue injection into perforating vessels, theoretically, minimizing the risk of embolization. [18] A limitation of this method is that it may be difficult and time-consuming to determine the exact feeding vessel. Injection of contrast has been proposed, prior to glue injection, to ensure that the correct afferent vessel was selected. [19] Endoscopic ultrasound-guided coil embolization An alternative method for treating gastric varices is EUS-guided coil embolization. By placing microcoils into the varices, obliteration is achieved. Synthetic fibers cover the coils, thereby promoting clot formation. The varix is identified and punctured by a standard EUS needle, after which the coils are advanced through the needle and into the varix, using the stylet as a "pusher." This technique was initially described as a case series and has been increasingly used both as a monotherapy and in combination with CYA. [20, 21] Endoscopic ultrasound-guided glue and coil combination therapy
Binmoeller et al. [20] reported the combined use of EUS-guided coil deployment with glue injection. The rationale was that the use of coils would facilitate the CYA injection by providing CYA a scaffold to form. [19] Binmoeller et al.'s study evaluated the treatment of patients with active recent bleeding due to large gastric varices and who were poor candidates for TIPS placement. In total, 30 patients were included, and they underwent combined treatment with EUS-guided coiling and CYA injection through a transesophageal route, thereby obviating a direct puncture of the gastric varix mucosa. A single coil was applied in the majority of patients (93%). Two patients developed esophageal bleeding at the needle injection site, which was treated with band ligation. The rebleeding rate was 16.6% after a 6.6-month follow-up. [20] The advantage of EUS-guided combined glue injection is the ability to perform treatment through the transesophageal route, thereby avoiding bleeding at the site of the gastric varix puncture. In the presence of active bleeding, this EUS transesophageal route could also be beneficial over a standard endoscopic approach from the stomach because the latter approach may be compromised by the presence of blood in the gastric lumen, obscuring the precise location of gastric variceal hemorrhage. Nevertheless, comparative prospective studies are needed to investigate the efficacy and cost-effectiveness of the combined treatment.
Ectopic variceal therapy
EUS-guided treatment has been applied in case reports regarding variceal bleeding at other anatomical locations. [22] The use of EUS-guided coil to stop massive variceal bleeding has been described. [23] Rectal varices are not uncommon, but they have a lower potential of bleeding than the esophageal and gastric varices. The use of both EUS-guided CYA injection and combined EUS-guided coil/CYA treatment for rectal varices has been reported. [24] EUS has also been applied to treat parastomal varices, [25] and although the data are insufficient to support EUS-guided treatment as first line in such cases, it has evolved as a promising modality for rescue treatment.
Nonvariceal gastrointestinal bleeding
EUS-guided treatment may be applied as an alternative modality to patients with refractory GI bleeding who have not responded to standard endoscopic treatment with epinephrine, hemoclips and electrosurgical coagulation. The data on EUS-guided techniques for nonvariceal GI bleeding have largely been confined to case reports. The treatment of bleeding from Dieulafoy lesions, GI stromal tumors, duodenal ulcers and hemosuccus pancreaticus has been reported in patients for whom conventional endoscopic and IR treatments had failed. [26] The methodology in most cases involved identification of feeder vessels and injection of sclerosing agents, with the confirmation of cessation of vascular flow by Doppler. Pseudoaneurysms are a rare and potentially lethal complication of pancreatitis or abdominal surgery.
Rupture of a pseudoaneurysm and the subsequent bleeding are typically treated by angiography or surgery and are associated with high morbidity and mortality. [27, 28] EUS-guided treatment for pancreatic pseudoaneurysm bleeding has been reported. [29] Law et al. [30] reported 17 cases of refractory pseudoaneurysm bleeding treated with a combination of glue, coils, alcohol and epinephrine injection using fine-needle EUS access with a linear echoendoscope.
Although such reports hold promise for an exciting future, the data available are not sufficient to support EUS-guided use over the standard therapies. Therefore, presently, EUS should be considered primarily in expert centers when other modalities are not technically feasible or have failed.
PORTAL VEIN: POTENTIAL APPLICATIONS

Portal vein access and pressure measurement
PV access can provide valuable information regarding patients with portal hypertension and other hepatobiliary diseases.
[31] EUS allows for transgastric or transduodenal access into PV, contrast injection and/or pressure monitoring, using a standard FNA needle. Initial approaches to EUS-guided PV interventions were developed in a porcine model. PV access and pressure measurement were first achieved using a 22G needle. [32] Subsequently, PV angiography in a porcine model was reported using a 25G needle. [33] Giday et al. [34] demonstrated that using carbon dioxide for portal venography obviated the need for injecting any contrast media. The same group performed EUS-guided transhepatic PV catheterization with a modified endoscopic retrograde cholangiography catheter. [35] The authors used a transhepatic puncture approach of the PV to reduce the risk of bleeding. Necropsy examination did not show any signs of bleeding or any vascular damage.
In the first human pilot study of EUS-guided portal pressure gradient measurement, 28 patients with a history of chronic liver disease or suspected cirrhosis underwent EUS-guided PV puncture with a 25G FNA needle attached to a newly developed compact manometer (Cook Medical, Bloomington, Ind) [ Figures 1 and 2] . [36] The patients also underwent standard upper endoscopy to investigate if the findings were consistent with portal hypertension. Measurements were recorded in the intrahepatic PV close to its bifurcation and in the HV approximately 2 cm from its takeoff from the intrahepatic inferior vena cava. Correlation of the measured portal pressure gradients with clinical parameters of portal hypertension (varices and portal hypertensive gastropathy) was noted and no adverse events were reported.
Intrahepatic portosystemic shunt
Rescue therapy for refractory gastroesophageal bleeding is the placement of TIPS, which currently requires transjugular access. The first insertion of an intrahepatic portosystemic shunt (IPSS) by EUS was performed in a porcine model in 2009. [37] The authors were able to identify a sonographic plane that achieved simultaneous visualization of the intrahepatic branches and of HV and PV. Under EUS guidance, the HV was punctured with a 19G needle that traversed the hepatic parenchyma. A self-expandable uncovered metal biliary stent was placed between the HV and PV, forming an IPSS. No adverse events were reported at 2 weeks postprocedure or at necropsy of the animals. Binmoeller et al. [38] used a similar method to create an IPSS using a lumen-apposing stent, also in a porcine model. No evidence of vascular or tissue injury was noted in necropsy. To date, this approach has not yet been reported in humans, but further development of this technique is anticipated.
Endoscopic ultrasound-guided fine-needle aspiration of portal vein thrombosis for staging of hepatocellular carcinoma
Curative resection or liver transplantation is contraindicated in case of hepatocellular carcinoma invading the PV. [39, 40] Endosonography may be useful in differentiating a benign thrombus from a tumor thrombus by providing cytopathologic confirmation using FNA. Transabdominal ultrasound sampling is limited by the potential of sample contamination with normal hepatocytes or tumor tissues, as the needle passes through the liver, and there is also a risk of serious biliary or vascular injury, depending on the path of the needle. [41] EUS-guided FNA is an alternative approach that may offer a more direct access, particularly to the extrahepatic PV, which can be accessed directly, as the needle is not required to pass through the hepatic parenchyma. In several case reports, malignant PV thrombi were diagnosed using an EUS-FNA transduodenal approach without adverse events. [41] [42] [43] [44] The diagnosis of hepatocellular carcinoma has also been reported by EUS-FNA of malignant PV thrombi in patients with no evidence of liver mass depicted on cross-sectional imaging. [41, 42] 
Endoscopic ultrasound-guided portal vein sampling of circulating tumor cells in pancreatobiliary malignancies
Circulating tumor cells (CTCs) migrate from the primary tumor through the vasculature to distant sites while maintaining similar characteristics to those of the tumor of origin. [45] A recent study showed that CTCs were found in PV blood samples (obtained by portal venous puncture at the time of surgical resection) in 58% of patients undergoing pancreaticoduodenectomy for resectable pancreatic or periampullary cancer [ Figure 3 ]. [46] A high CTC count in PV samples has been found to a useful predictor for the future development of liver metastases. EUS sampling of CTCs before and during cancer treatment may, in the future, provide a window into treatment progress and changes in tumor biology in response to therapy. It is also conceivable that CTCs could have a potential use for developing cell lines, human tumor xenografts and organoids to test treatments and evaluate drug resistance mechanisms. [47] Endoscopic ultrasound-guided portal injection chemotherapy using drug-eluting microbeads Treatment options for patients with diffuse hepatic metastases are limited to systemic palliative chemotherapy. Transarterial microbead administration into the hepatic artery can lead to ischemic biliary strictures because the bile duct receives its blood supply from the hepatic artery. EUS-guided PV injection of chemotherapy (EPIC) may be a better approach to target the liver parenchyma while sparing the bile duct. EPIC was first reported in a porcine study demonstrating EUS-PV injection of drug-eluting microbeads or nanoparticles. [48] The study showed that EPIC is feasible and results in higher hepatic concentrations of the chemotherapeutic agent (irinotecan) and lower systemic levels of the agent, compared with systemic administration. This approach may prove to be advantageous in a wide variety of clinical conditions for which prolonged, targeted hepatic drug exposure is desired.
Selective portal vein embolization
Selective PV embolization of either the right or left PV branch to achieve compensatory hypertrophy of the contralateral hepatic lobe before resection for hepatic malignancy has been reported. [49] An animal model study demonstrated that EUS-guided microcoil embolization of the right PV can result in hypertrophy of the right hepatic lobe. In a proof-of-concept study, the authors injected an ethylene-vinyl alcohol copolymer into the main PV of a Yorkshire pig and achieved an immediate increase in PV pressure from a baseline of 3-15 mmHg. In addition, a solid thrombus was identified in the main PV during necropsy, extending to the left PV on Day 7.
[49]
ACCESS TO THE HEART
The heart and pulmonary trunk are in proximity to the esophagus, and thus directly accessible to EUS. This anatomic relationship is routinely used in cardiology for transesophageal echocardiography. [50, 51] A successful EUS-guided puncture of the heart in a survival porcine study was followed by three clinical cases. [52] In the animal group, the authors performed EUS-guided access to the left atrium, left ventricle, coronary arteries and aortic valve. No adverse events were reported. At necropsy, the puncture sites were identified, but were unremarkable in appearance. Subsequently, the authors proceeded with EUS-cardiac access in humans. Pericardial fluid aspiration was performed in two patients, and an FNA of a 5-cm left atrial mass in the third patient. No adverse events were reported. EUS-guided FNA of a right atrial mass and a pericardial tumor has also been reported. [53, 54] 
CONCLUSION
The GI system can provide unique access approaches to vascular structures in the abdomen, pelvis and mediastinum. The evolution of EUS technology has led to the development of many new EUS-guided vascular interventions, although the clinical experience in humans is currently extremely limited. There is a great deal of opportunity for endoscopists to take on the expanding roles in the management of a wide variety of GI and liver conditions, and access to the vasculature represents an important new territory. The development of new approaches and dedicated equipment for EUS-guided vascular intervention is enthusiastically awaited.
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